Clearside Biomedical (CLSD) shares fell 31% in recent Friday trading after downgrades by at least five analysts.
Stifel downgraded the stock to neutral from buy and cut its price target to $2 from $8. Chardan lowered its rating to neutral from buy and withdrew its $6 price target. HC Wainwright, Needham and Jones Trading also issued downgrades.
Clearside's intraday volume topped 3.08 million shares versus the daily average of 238,151.
Price: 0.41, Change: -0.19, Percent Change: -31.37
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.